Page 285 - Read Online

Zhang et al. Hepatoma Res 2019;5:27 I http://dx.doi.org/10.20517/2394-5079.2019.13 Page 15 of 18

anti-miR-27a in liver cancer theranostics. Theranostics 2018;8:3808-23.
85 Rani B, Malfettone A, Dituri F, Soukupova J, Lupo L, et al. Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma
by modulating CD44 expression. Cell Death Dis 2018;9:373.
86 Badawi M, Kim J, Dauki A, Sutaria D, Motiwala T, et al. CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to
the ATP-competitive mTOR inhibitor INK128. Oncotarget 2018;9:26032-45.
87 Reif AE, Allen JM. THE AKR THYMIC ANTIGEN AND ITS DISTRIBUTION IN LEUKEMIAS AND NERVOUS TISSUES. J Exp
Med 1964;120:413-33.
88 Schlesinger M, Yron I. Antigenic changes in lymph-node cells after administration of antiserum to thymus cells. Science 1969;164:1412-3.
89 Ades EW, Zwerner RK, Acton RT, Balch CM. Isolation and partial characterization of the human homologue of Thy-1. J Exp Med
1980;151:400-6.
90 Rege TA, Hagood JS. Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration,
cancer, and fibrosis. FASEB J 2006;20:1045-54.
91 Zhang K, Che S, Pan C, Su Z, Zheng S, et al. The SHH/Gli axis regulates CD90-mediated liver cancer stem cell function by activating
the IL6/JAK2 pathway. J Cell Mol Med 2018;22:3679-90.
92 Nomura Y, Yamashita T, Oishi N, Nio K, Hayashi T, et al. De novo emergence of mesenchymal stem-like CD105 + cancer cells by
cytotoxic agents in human hepatocellular carcinoma. Transl Oncol 2017;10:184-9.
93 Jia Q, Zhang X, Deng T, Gao J. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver
cancer stem cells. Cell Reprogram 2013;15:143-50.
94 Zhu L, Zhang W, Wang J, Liu R. Evidence of CD90+CXCR4+ cells as circulating tumor stem cells in hepatocellular carcinoma. Tumour
Biol 2015;36:5353-60.
95 Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, et al. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human
hepatocellular carcinoma. Hepatology 2013;57:1484-97.
96 Wang Y, Wang B, Xiao S, Li Y, Chen Q. miR-125a/b inhibits tumor-associated macrophages mediated in cancer stem cells of
hepatocellular carcinoma by targeting CD90. J Cell Biochem 2019;120:3046-55.
97 Zhang K, Che S, Su Z, Zheng S, Zhang H, et al. CD90 promotes cell migration, viability and sphere-forming ability of hepatocellular
carcinoma cells. Int J Mol Med 2018;41:946-54.
98 Lu JW, Chang JG, Yeh KT, Chen RM, Tsai JJ, et al. Overexpression of Thy1/CD90 in human hepatocellular carcinoma is associated with
HBV infection and poor prognosis. Acta Histochem 2011;113:833-8.
99 Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies.
Proc Natl Acad Sci U S A 1979;76:1438-42.
100 Sears HF, Atkinson B, Mattis J, Ernst C, Herlyn D, et al. Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal
tumours. Lancet 1982;1:762-5.
101 Sears HF, Herlyn D, Steplewski Z, Koprowski H. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal
adenocarcinoma. J Biol Response Mod 1984;3:138-50.
102 Baeuerle P, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007;96:417-23.
103 Schmelzer E, Reid LM. EpCAM expression in normal, non-pathological tissues. Front Biosci 2008;13:3096-100.
104 Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in
hepatocellular carcinoma. Cancer Res 2007;67:10831-9.
105 Nio K, Yamashita T, Okada H, Kondo M, Hayashi T, et al. Defeating EpCAM + liver cancer stem cells by targeting chromatin remodeling
enzyme CHD4 in human hepatocellular carcinoma. J Hepatol 2015;63:1164-72.
106 Yamashita T, Honda M, Nio K, Nakamoto Y, Yamashita T, et al. Oncostatin m renders epithelial cell adhesion molecule-positive liver
cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. Cancer Res 2010;70:4687-97.
107 Zhang Y, Guan DX, Shi J, Gao H, Li JJ, et al. All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing
differentiation of tumor initiating cells in liver cancer. J Hepatol 2013;59:1255-63.
108 Chiba T, Suzuki E, Negishi M, Saraya A, Miyagi S, et al. 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of
tumor-initiating hepatocellular carcinoma cells. Int J Cancer 2012;130:2557-67.
109 Ji J, Zheng X, Forgues M, Yamashita T, Wauthier EL, et al. Identification of microRNAs specific for epithelial cell adhesion molecule-
positive tumor cells in hepatocellular carcinoma. Hepatology 2015;62:829-40.
110 Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug
resistance and recurrence of liver cancer. Hepatology 2013;58:629-41.
111 Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, et al. Identification of microRNA-181 by genome-wide screening as a critical player in
EpCAM–positive hepatic cancer stem cells. Hepatology 2009;50:472-80.
112 Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of
hepatocellular carcinoma. Cancer Res 2008;68:1451-61.
113 Chen J, Liu Q, Xiao J, Du J. EpCAM-antibody-labeled noncytotoxic polymer vesicles for cancer stem cells-targeted delivery of
anticancer drug and siRNA. Biomacromolecules 2015;16:1695-705.
114 Saito T, Chiba T, Yuki K, Zen Y, Oshima M, et al. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma
cells. PLoS One 2013;8:e70010.
115 Babaei M, Abnous K, Taghdisi SM, Amel Farzad S, Peivandi MT, et al. Synthesis of theranostic epithelial cell adhesion molecule
targeted mesoporous silica nanoparticle with gold gatekeeper for hepatocellular carcinoma. Nanomedicine (Lond) 2017;12:1261-79.